Across all study participants, 34.4% of those treated with FB102 reached FVASI50 and 12.5% attained FVASI75 at week 24.
Phase transformations—in which a material changes from one crystal structure to another, thereby acquiring dramatically ...
Unbiased cerebrospinal fluid proteomics identify coordinated increases in HDL-like lipid transport proteins and myelination pathways following investigational Spectris sensory stimulation Cognito ...
Globally recognized leader in early-phase oncology clinical development and experimental therapeuticsStrengthens strategic ...
ASCO 2026 highlighted a shift toward precision-driven oncology R&D, where biomarkers, ctDNA, and integrated strategies guide ...
Sionna Therapeutics targets cystic fibrosis with novel CFTR/NBD1 stabilization; key 2026 readouts and cash runway to 2028.
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of Dominic Borie, M.D., ...
Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the evaluable 3 mg/kg and 6 mg/kg cohortsAX-0810 demonstrated up ...
In regulatory news in June 2026, the US FDA accepted the first in silico drug development tool as part of its ISTAND program, ...
When Vera Therapeutics in-licensed atacicept from Merck KGaA about six years ago, patients with IgA nephropathy (IgAN) had no ...
Anthropic’s new Claude research reveals a hidden internal “global workspace” that resembles human conscious processing, ...
Evommune, Inc. (NYSE: EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results